PT2598533T - Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada - Google Patents
Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenadaInfo
- Publication number
- PT2598533T PT2598533T PT11813204T PT11813204T PT2598533T PT 2598533 T PT2598533 T PT 2598533T PT 11813204 T PT11813204 T PT 11813204T PT 11813204 T PT11813204 T PT 11813204T PT 2598533 T PT2598533 T PT 2598533T
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- fusion proteins
- human protein
- protein fragments
- natural human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36846510P | 2010-07-28 | 2010-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2598533T true PT2598533T (pt) | 2019-05-08 |
Family
ID=45530725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT11813204T PT2598533T (pt) | 2010-07-28 | 2011-07-28 | Proteínas de fusão de fragmentos de proteínas humanas naturais para criar composições fc de imunoglobulina multimerizada de forma ordenada |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130156765A1 (pt) |
| EP (2) | EP2598533B1 (pt) |
| JP (2) | JP5826270B2 (pt) |
| KR (3) | KR102148265B1 (pt) |
| CN (2) | CN103154036B (pt) |
| AR (1) | AR082404A1 (pt) |
| AU (1) | AU2011282579B2 (pt) |
| BR (1) | BR112013002074B1 (pt) |
| CA (2) | CA2804512C (pt) |
| DK (1) | DK2598533T3 (pt) |
| ES (1) | ES2719623T3 (pt) |
| HR (1) | HRP20190652T1 (pt) |
| HU (1) | HUE044869T2 (pt) |
| IL (3) | IL224427A (pt) |
| MX (3) | MX347343B (pt) |
| PL (1) | PL2598533T3 (pt) |
| PT (1) | PT2598533T (pt) |
| SI (1) | SI2598533T1 (pt) |
| TR (1) | TR201906652T4 (pt) |
| TW (2) | TWI588157B (pt) |
| WO (1) | WO2012016073A2 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8680237B2 (en) | 2007-06-01 | 2014-03-25 | Gliknik Inc. | Immunoglobulin constant region FC receptor binding agents |
| US20100143353A1 (en) * | 2008-12-04 | 2010-06-10 | Mosser David M | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME |
| BR112013002074B1 (pt) | 2010-07-28 | 2021-09-14 | Gliknik Inc | Composto homodimérico, dímero ou multímero de ordem superior do composto homodimérico, composição, composto, multímero e usos dos mesmos |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2014031646A2 (en) * | 2012-08-20 | 2014-02-27 | Gliknik Inc. | Molecules with antigen binding and polyvalent fc gamma receptor binding activity |
| RU2015118063A (ru) * | 2012-10-17 | 2016-12-10 | Ливерпуль Скул Оф Тропикал Медисин | Иммуномодулирующие белки |
| WO2014168715A1 (en) * | 2013-04-08 | 2014-10-16 | R-Pharm Overseas, Inc. | B7 ligands/cd20 inhibitor composition and use thereof |
| US20170007685A1 (en) * | 2013-11-05 | 2017-01-12 | The Board Of Regents Of The University Of Texas System | TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES |
| US10745463B2 (en) | 2013-11-18 | 2020-08-18 | University Of Maryland, Baltimore | Hyper-glycosylated antibodies with selective Fc receptor binding |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| SG11201606597QA (en) | 2014-03-05 | 2016-09-29 | Ucb Biopharma Sprl | Multimeric fc proteins |
| SG11201607070VA (en) | 2014-05-02 | 2016-11-29 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| US20180044416A1 (en) * | 2015-03-05 | 2018-02-15 | Ucb Biopharma Sprl | Polymeric Fc proteins and methods of screening to alter their functional characteristics |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| EP3325011B3 (en) * | 2015-07-24 | 2023-03-15 | Gliknik Inc. | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding |
| AU2017245143B2 (en) | 2016-03-30 | 2024-01-11 | Ab Biosciences, Inc. | Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CA3025306A1 (en) | 2016-05-23 | 2017-11-30 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| WO2017214321A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
| BR112019001156A2 (pt) * | 2016-07-22 | 2019-04-30 | Gliknik Inc | proteínas de fusão de fragmentos de proteína humana para criar composições de fc de imunoglobulina multimerizadas ordenadas com ligação de receptor fc reforçada |
| CN110177802A (zh) | 2016-12-09 | 2019-08-27 | 格利克尼克股份有限公司 | 多聚化stradomer GL-2045的制造优化 |
| IL266988B1 (en) | 2016-12-09 | 2024-07-01 | Gliknik Inc | Methods for the treatment of inflammatory disorders with multivalent FC compounds |
| BR112019013955A2 (pt) | 2017-01-06 | 2020-02-11 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos de fc manipulados |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| JP7351835B2 (ja) | 2017-12-14 | 2023-09-27 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体 |
| BR112022003713A2 (pt) | 2019-09-13 | 2022-08-09 | CSL Behring Lengnau AG | Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo |
| CA3179834A1 (en) * | 2020-06-25 | 2021-12-30 | David S. Block | Ace2-fc fusion proteins and methods of use |
| KR20230061710A (ko) * | 2021-10-29 | 2023-05-09 | 주식회사 이뮤노로지컬디자이닝랩 | Cadm1을 인식하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004781A (en) | 1988-01-22 | 1999-12-21 | The General Hospital Corporation | Nucleic acid encoding Ig-CD4 fusion proteins |
| GB8824869D0 (en) | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
| US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
| US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
| AU664561B2 (en) | 1991-06-21 | 1995-11-23 | University Of Cincinnati, The | Orally administrable therapeutic proteins and method of making |
| IL102915A (en) | 1992-01-19 | 2005-12-18 | Yeda Res & Dev | Soluble ldl receptor and its preparation |
| EP0664710A4 (en) | 1992-08-07 | 1998-09-30 | Progenics Pharm Inc | CD4-GAMMA2 AND CD4-IgG2 NON-PEPTIDYL CONJUGATE IMMUNOCONJUGATES AND USES THEREOF. |
| EP0680337A4 (en) | 1993-01-12 | 1997-07-30 | Anthony George Gristina | METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY. |
| US5877396A (en) | 1993-04-23 | 1999-03-02 | Sloan Kettering Institute For Cancer Research | Mice mutant for functional Fc receptors and method of treating autoimmune diseases |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US20020147326A1 (en) | 1996-06-14 | 2002-10-10 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| WO1999056777A1 (en) | 1998-05-06 | 1999-11-11 | Temple University - Of The Commonwealth System Of Higher Education | REVERSAL OF PROINFLAMMATORY RESPONSE BY LIGATING THE MACROPHAGE FcηRI RECEPTOR |
| US7250494B2 (en) | 1998-06-15 | 2007-07-31 | Biosynexus Incorporated | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
| US6933326B1 (en) | 1998-06-19 | 2005-08-23 | Lifecell Coporation | Particulate acellular tissue matrix |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| AU2926401A (en) | 2000-01-03 | 2001-07-16 | Tr Associates, L.L.C. | Novel chimeric proteins and methods for using the same |
| US7202349B2 (en) | 2001-01-12 | 2007-04-10 | Becton, Dickinson And Company | Intrinsically fluorescent, self-multimerizing MHC fusion proteins and complexes thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
| AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
| WO2002072608A2 (en) | 2001-03-09 | 2002-09-19 | University Of Chicago | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
| WO2002092784A2 (en) | 2001-05-15 | 2002-11-21 | Emory University | POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47 |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| US7094306B2 (en) | 2001-12-18 | 2006-08-22 | Dow Corning Toray Silicone Co., Ltd. | Photocurable organic polymer composition |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| WO2006061650A2 (en) | 2004-12-10 | 2006-06-15 | Trigen Gmbh | Methods, products and uses involving platelets and/or the vasculature |
| JP2008522583A (ja) | 2002-06-14 | 2008-07-03 | セントカー・インコーポレーテツド | 修飾“ｓ”抗体 |
| ES2392511T3 (es) | 2002-11-15 | 2012-12-11 | Musc Foundation For Research Development | Moduladores de complemento dianas sobre el receptor 2 de complemento |
| EP1596804A4 (en) | 2003-01-13 | 2008-02-06 | Macrogenics Inc | SOLUBLE FCyR FUSION PROTEINS AND METHODS OF USE |
| ES2327409T3 (es) | 2003-03-26 | 2009-10-29 | Apogenix Gmbh | Proteinas de fusion fc mejoradas. |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| US20070041972A1 (en) | 2003-05-30 | 2007-02-22 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| WO2005005604A2 (en) | 2003-06-30 | 2005-01-20 | Centocor, Inc. | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
| EP1691832A2 (en) | 2003-09-29 | 2006-08-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunoglobulins whith potent and broad antiviral activity |
| EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| WO2005089503A2 (en) | 2004-03-19 | 2005-09-29 | Progenics Pharmaceuticals, Inc. | Cd4-igg2 formulations |
| WO2006008739A2 (en) | 2004-07-19 | 2006-01-26 | Elutex Ltd. | Modified conductive surfaces having active substances attached thereto |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| WO2006113889A2 (en) | 2005-04-19 | 2006-10-26 | University Of Maryland | Compositions and methods for modulating interleukin-10 |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AU2006280587B2 (en) | 2005-08-16 | 2011-02-24 | Hanmi Science Co., Ltd. | A method for the mass production of immunoglobulin Fc region deleted initial methionine residues |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| CA2639115A1 (en) | 2006-02-17 | 2007-08-23 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases |
| JP5598894B2 (ja) | 2006-03-03 | 2014-10-01 | 学校法人東京理科大学 | 生物活性を強化した抗体改変体 |
| US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
| PL2368999T3 (pl) | 2007-05-11 | 2014-08-29 | Alexion Pharma Inc | Kierowana do kości fosfataza alkaliczna, zestawy oraz metody wykorzystywania |
| US20090252729A1 (en) | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
| LT2176298T (lt) * | 2007-05-30 | 2018-04-10 | Xencor, Inc. | Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui |
| US8680237B2 (en) | 2007-06-01 | 2014-03-25 | Gliknik Inc. | Immunoglobulin constant region FC receptor binding agents |
| AU2008265983B2 (en) | 2007-06-14 | 2013-06-20 | Galactica Pharmaceuticals, Inc. | RAGE fusion proteins |
| CN108129573B (zh) | 2007-09-21 | 2021-10-08 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| WO2009058564A2 (en) | 2007-11-01 | 2009-05-07 | Maxygen, Inc. | Immunosuppressive polypeptides and nucleic acids |
| US20100143353A1 (en) | 2008-12-04 | 2010-06-10 | Mosser David M | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME |
| EP2499165B1 (en) | 2009-11-13 | 2016-09-14 | Grifols Therapeutics Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| GB0922209D0 (en) | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| US20130209463A1 (en) | 2010-06-30 | 2013-08-15 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| AU2015200330B2 (en) | 2010-07-28 | 2016-10-27 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions |
| BR112013002074B1 (pt) | 2010-07-28 | 2021-09-14 | Gliknik Inc | Composto homodimérico, dímero ou multímero de ordem superior do composto homodimérico, composição, composto, multímero e usos dos mesmos |
| WO2013112986A1 (en) | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| WO2014031646A2 (en) | 2012-08-20 | 2014-02-27 | Gliknik Inc. | Molecules with antigen binding and polyvalent fc gamma receptor binding activity |
| WO2016073917A1 (en) | 2014-11-06 | 2016-05-12 | Gliknik Inc. | Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose |
| EP3325011B3 (en) | 2015-07-24 | 2023-03-15 | Gliknik Inc. | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding |
| IL262010B (en) | 2016-04-04 | 2022-09-01 | Bioverativ Usa Inc | Anti-complement factor bb antibodies and their uses |
| WO2017214321A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
| IL266988B1 (en) | 2016-12-09 | 2024-07-01 | Gliknik Inc | Methods for the treatment of inflammatory disorders with multivalent FC compounds |
-
2011
- 2011-07-28 BR BR112013002074-1A patent/BR112013002074B1/pt active IP Right Grant
- 2011-07-28 AU AU2011282579A patent/AU2011282579B2/en active Active
- 2011-07-28 KR KR1020187012379A patent/KR102148265B1/ko active IP Right Grant
- 2011-07-28 MX MX2013001148A patent/MX347343B/es active IP Right Grant
- 2011-07-28 ES ES11813204T patent/ES2719623T3/es active Active
- 2011-07-28 CN CN201180046311.6A patent/CN103154036B/zh active Active
- 2011-07-28 TR TR2019/06652T patent/TR201906652T4/tr unknown
- 2011-07-28 CA CA2804512A patent/CA2804512C/en active Active
- 2011-07-28 HU HUE11813204A patent/HUE044869T2/hu unknown
- 2011-07-28 KR KR1020207023918A patent/KR20200111213A/ko not_active Application Discontinuation
- 2011-07-28 WO PCT/US2011/045768 patent/WO2012016073A2/en active Application Filing
- 2011-07-28 EP EP11813204.2A patent/EP2598533B1/en active Active
- 2011-07-28 AR ARP110102729A patent/AR082404A1/es active IP Right Grant
- 2011-07-28 TW TW105116005A patent/TWI588157B/zh active
- 2011-07-28 PL PL11813204T patent/PL2598533T3/pl unknown
- 2011-07-28 SI SI201131710T patent/SI2598533T1/sl unknown
- 2011-07-28 CN CN201610238182.5A patent/CN105820256A/zh active Pending
- 2011-07-28 EP EP19157219.7A patent/EP3543257A1/en active Pending
- 2011-07-28 DK DK11813204.2T patent/DK2598533T3/en active
- 2011-07-28 KR KR1020137002321A patent/KR102066996B1/ko active IP Right Grant
- 2011-07-28 PT PT11813204T patent/PT2598533T/pt unknown
- 2011-07-28 CA CA2902942A patent/CA2902942C/en active Active
- 2011-07-28 JP JP2013521984A patent/JP5826270B2/ja active Active
- 2011-07-28 US US13/812,269 patent/US20130156765A1/en not_active Abandoned
- 2011-07-28 TW TW100126848A patent/TWI542597B/zh active
- 2011-07-28 MX MX2016009799A patent/MX368531B/es unknown
-
2013
- 2013-01-27 IL IL224427A patent/IL224427A/en active IP Right Grant
- 2013-01-28 MX MX2019012016A patent/MX2019012016A/es unknown
-
2015
- 2015-07-03 JP JP2015134698A patent/JP6225142B2/ja active Active
-
2017
- 2017-07-05 US US15/642,175 patent/US11117940B2/en active Active
- 2017-09-28 IL IL254796A patent/IL254796B/en active IP Right Grant
-
2019
- 2019-04-05 HR HRP20190652TT patent/HRP20190652T1/hr unknown
- 2019-08-15 IL IL268724A patent/IL268724B/en unknown
-
2021
- 2021-08-12 US US17/400,367 patent/US12084482B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268724B (en) | Proteins are fused from natural human protein fragments to create ordered immunoglobulin multimer fc preparations | |
| HK1254447A1 (zh) | 形成補體結合增强的有序多聚化免疫球蛋白fc組合物的人類蛋白質片段融合蛋白質 | |
| ZA201400490B (en) | Arginine- free tnfr: fc- fusion polypeptide compositions and methods of use | |
| ZA201208906B (en) | Humanised antigen binding proteins to myostatin6 | |
| EP2970490A4 (en) | Antibodies to mica and micb proteins | |
| IL232219B (en) | Human or humanized antibodies against tar-dna-binding protein 43kda and their uses | |
| IL216680A (en) | Growth hormone fusion protein containing human growth hormone attached to an elongated polypeptide | |
| EP2744517A4 (en) | COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL ANTI-PROTEIN ANTIBODIES | |
| PL2697257T3 (pl) | Białka fuzyjne fc o nowatorskim układzie lub zawierające nowatorskie łączniki | |
| EP2723380A4 (en) | HYBRID LIGHT CHAIN IMMUNOGLOBULIN PROTEINS AND METHODS OF USE THEREOF | |
| EP3000825A4 (en) | Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein | |
| PT2919801T (pt) | Composição farmacêutica estável da proteína de fusão tnfr:fc etanercept | |
| HK1213775A1 (zh) | 噬菌體的 融合蛋白作爲澱粉樣蛋白結合劑的用途 | |
| EP2797629A4 (en) | AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF | |
| IL223665B (en) | Human antibodies to human cytomegalovirus gb (cmv) protein | |
| HK1178935A1 (zh) | 含增強免疫應答的 融合蛋白的方法和組合物 | |
| IL264257A (en) | Fusion proteins of human protein fragments to create ordered multimeric fc immunoglobulin preparations with improved fc receptor binding | |
| IL241417A0 (en) | Modification and new compositions of human scartoglobin proteins | |
| EP2383336A4 (en) | PEPTIDE CAPABLE OF BINDING TO AN IMMUNOGLOBULIN | |
| EP2886556A4 (en) | MONOCLONAL ANTIBODY WHICH BINDERS SPECIFICALLY TO THE TM4SF5 PROTEIN AND USE THEREOF | |
| EP2623512A4 (en) | PEPTIDE THAT COULD BIND TO IMMUNOGLOBULIN |